Key result
Early initiation of tafamidis for transthyretin amyloid cardiomyopathy provides substantial survival benefit in earlier stages but remains above commonly cited willingness-to-pay ranges at current Japanese prices.
Why the study?
Does earlier initiation of tafamidis provide cost-effective survival benefit in patients with ATTR-CM across different NAC stages?
Does earlier initiation of tafamidis provide cost-effective survival benefit in patients with ATTR-CM across different NAC stages?
This editorial highlights that while earlier initiation of tafamidis in ATTR-CM yields greater absolute survival benefits, it is currently not cost-effective at Japanese reimbursement prices, underscoring the gap between biological efficacy and economic affordability.
required substantially longer follow-up.The supplementary analysis summarized "time to benefit" as approximately 18 months in stage I and 56 months in stage II, with no demonstrable time to benefit in stage III within the available follow-up. 6,9The economic message is equally important.Even where clinical benefit was greatest, economic value at the current Japanese reimbursement price remained unfavorable: the lowest estimated incremental cost-effectiveness ratios (ICERs) were approximately ¥47 million/QALY in stage I and ¥52 million/QALY in stage II, both above commonly cited Japanese willingness-to-pay ranges.6,7 Stage III was far less favorable.Utility assumptions changed estimates only modestly, whereas drug price dominated the model; reductions of roughly 68% and 71% were estimated to bring stages I and II, respectively, to ¥15 million/QALY.6 Thus, "earlier is better" and "earlier is cost-effective" are not synonymous.This distinction is clinically useful.Earlier detection is supported by Japanese evidence, including hs-cTnT-based screening and opportunistic imaging approaches, 2,3 while long-term observational data suggest biomarkers may help identify poorer prognosis during tafamidis therapy.4 Nagata et al. add the missing value dimension: diagnostic acceleration is most meaningful when it moves treatment into a stage in which patients can accumulate substantial survival benefit, but diagnosis alone cannot solve affordability.6 However, several uncertainties should prevent these ICERs from being interpreted as definitive reimbursement thresholds.First, this is not a conventional lifetime costutility model.The comparator is delayed tafamidis rather than persistent no treatment; non-drug healthcare costs are omitted; outcomes are not discounted; and QALYs are derived from RMST using assumed utility weights rather than longitudinal patient-level EQ-5D measurements.6 These choices are understandable, but the analysis is best viewed as a stage-specific value signal rather than a complete health technology assessment.Second, reconstructing
No takes yet. Share an insight, caveat, or question.
Takuya Kishi (2026) conducted an editorial in Transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis vs. Delayed tafamidis was evaluated on Absolute survival benefit using restricted mean survival time (RMST) and incremental cost-effectiveness ratio (ICER). Early initiation of tafamidis for transthyretin amyloid cardiomyopathy provides substantial survival benefit in earlier stages but remains above commonly cited willingness-to-pay ranges at current Japanese prices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: